BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30173131)

  • 1. Mitotane-induced dyspnoea: an unusual side effect.
    Farooq AU; Amjad W; Kochar T; Adhikari S
    BMJ Case Rep; 2018 Sep; 2018():. PubMed ID: 30173131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Mitotane in the treatment of adrenal carcinoma].
    Sane T
    Duodecim; 2010; 126(17):2040-6. PubMed ID: 21053521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-Dose Mitotane-Induced Encephalopathy in the Treatment of Adrenocortical Carcinoma.
    Pape E; Feliu C; Yéléhé-Okouma M; Colling N; Djerada Z; Gambier N; Weryha G; Scala-Bertola J
    Oncologist; 2018 Mar; 23(3):389-390. PubMed ID: 29192018
    [No Abstract]   [Full Text] [Related]  

  • 4. Subacute Cutaneous Lupus Erythematosus Induced by Mitotane.
    Mayor-Ibarguren A; Roldán-Puchalt MC; Gómez-Fernández C; Albízuri-Prado F; Álvarez-Escola C
    JAMA Dermatol; 2016 Jan; 152(1):109-11. PubMed ID: 26444320
    [No Abstract]   [Full Text] [Related]  

  • 5. Contribution of Therapeutic Monitoring in the Assessment of Toxic Adverse Effects of Mitotane: a Case Report.
    Jebabli N; Gaïes E; Eljebari H; Charfi R; Lakhal M; Klouz A; Salouage I; Trabelsi S
    Therapie; 2015; 70(6):545-6. PubMed ID: 26242497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian cyst formation in women of reproductive age receiving mitotane as part of the treatment of adrenocortical carcinoma: Clinical and experimental observations.
    Abrahamsson G; Ekerhovd E; Janson PO; Jansson S; Ahlman H; Wängberg B; Norström A
    Acta Obstet Gynecol Scand; 2020 Oct; 99(10):1297-1302. PubMed ID: 32282928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of mitotane in the treatment of adrenocortical carcinoma: A retrospective study in 34 Belgian patients.
    Maiter D; Bex M; Vroonen L; T'Sjoen G; Gil T; Banh C; Chadarevian R
    Ann Endocrinol (Paris); 2016 Oct; 77(5):578-585. PubMed ID: 27063476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pregnancy in a patient with adrenocortical carcinoma during treatment with Mitotane - a case report.
    Baszko-Błaszyk D; Ochmańska K; Waśko R; Sowiński J
    Endokrynol Pol; 2011; 62(2):186-8. PubMed ID: 21528483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma.
    Kerkhofs TM; Baudin E; Terzolo M; Allolio B; Chadarevian R; Mueller HH; Skogseid B; Leboulleux S; Mantero F; Haak HR; Fassnacht M
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4759-67. PubMed ID: 24057287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A CASE REPORT: A PATIENT WITH METASTATIC ADRENOCORTICAL CARCINOMA EXCLUSIVELY TREATED WITH MITOTANE WITH LONG-TERM FOLLOW-UP].
    Yamashita D; Hanai T; Onuki T; Suzuki K; Nakayama T
    Nihon Hinyokika Gakkai Zasshi; 2019; 110(1):12-17. PubMed ID: 31956212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Normalisation of contralateral adrenal function after long-term mitotane therapy in a girl after surgical treatment of adrenocortical carcinoma].
    Lecka A; Ginalska-Malinowska M
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):234-6. PubMed ID: 17020662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International consensus on mitotane treatment in pediatric patients with adrenal cortical tumors: indications, therapy, and management of adverse effects.
    Riedmeier M; Antonini SRR; Brandalise S; Costa TEJB; Daiggi CM; de Figueiredo BC; de Krijger RR; De Sá Rodrigues KE; Deal C; Del Rivero J; Engstler G; Fassnacht M; Fernandes Luiz Canali GC; Molina CAF; Gonc EN; Gültekin M; Haak HR; Guran T; Hendriks Allaird EJ; Idkowiak J; Kuhlen M; Malkin D; Meena JP; Pamporaki C; Pinto E; Puglisi S; Ribeiro RC; Thompson LDR; Yalcin B; Van Noesel M; Wiegering V
    Eur J Endocrinol; 2024 Mar; 190(4):G15-G24. PubMed ID: 38552173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant mitotane in adrenocortical carcinoma.
    Lee JE
    N Engl J Med; 2007 Sep; 357(12):1258; author reply 1259. PubMed ID: 17891836
    [No Abstract]   [Full Text] [Related]  

  • 14. Adjuvant mitotane treatment for adrenocortical carcinoma.
    Terzolo M; Angeli A; Fassnacht M; Daffara F; Tauchmanova L; Conton PA; Rossetto R; Buci L; Sperone P; Grossrubatscher E; Reimondo G; Bollito E; Papotti M; Saeger W; Hahner S; Koschker AC; Arvat E; Ambrosi B; Loli P; Lombardi G; Mannelli M; Bruzzi P; Mantero F; Allolio B; Dogliotti L; Berruti A
    N Engl J Med; 2007 Jun; 356(23):2372-80. PubMed ID: 17554118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.
    Terzolo M; Baudin AE; Ardito A; Kroiss M; Leboulleux S; Daffara F; Perotti P; Feelders RA; deVries JH; Zaggia B; De Francia S; Volante M; Haak HR; Allolio B; Al Ghuzlan A; Fassnacht M; Berruti A
    Eur J Endocrinol; 2013 Sep; 169(3):263-70. PubMed ID: 23704714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant mitotane in adrenocortical carcinoma.
    Dickstein G; Shechner C; Nativ O
    N Engl J Med; 2007 Sep; 357(12):1257-8; author reply 1259. PubMed ID: 17891838
    [No Abstract]   [Full Text] [Related]  

  • 17. Oral and vulvo-vaginal lichenoid reactions due to mitotane (Lysodren): A case report.
    Schmouchkovitch A; Herry H; Thuillier P; Kerlan V; Fleuret C; Le Toux G; Boisramé S
    Medicine (Baltimore); 2017 Jan; 96(2):e5075. PubMed ID: 28079787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant mitotane in adrenocortical carcinoma.
    Bertherat J; Coste J; Bertagna X
    N Engl J Med; 2007 Sep; 357(12):1256-7; author reply 1259. PubMed ID: 17881760
    [No Abstract]   [Full Text] [Related]  

  • 19. Metabolic and hormonal side effects of mitotane treatment for adrenocortical carcinoma: A retrospective study in 50 Danish patients.
    Vikner ME; Krogh J; Daugaard G; Andreassen M
    Clin Endocrinol (Oxf); 2021 Feb; 94(2):141-149. PubMed ID: 32996176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up.
    Mauclère-Denost S; Leboulleux S; Borget I; Paci A; Young J; Al Ghuzlan A; Deandreis D; Drouard L; Tabarin A; Chanson P; Schlumberger M; Baudin E
    Eur J Endocrinol; 2012 Feb; 166(2):261-8. PubMed ID: 22048971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.